Alembic Pharma LTD

Alembic Pharma Ltd (APLLTD) is a small-cap Healthcare company valued at ₹15,518 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Alembic Pharma Ltd last traded at ₹790, modestly down 0.33% on the day.

Recent developments

On 2026-08-04, Alembic Pharma reported its Q1 results, showing a 26% rise in revenue to ₹2,150 crore and a 12% increase in net profit to ₹172 crore. The company also highlighted a 49% growth in US formulation sales and single-digit growth in India operations. On 2026-07-19, Alembic Pharma's partner NATCO received a USFDA tentative nod for generic Olaparib tablets, expanding the company's USFDA ANDA approvals to 244, with 224 final approvals and 20 tentative approvals.

Financial performance

The company's business is improving, with annual revenue rising 10.1% and annual net profit growing 15.3%. The latest quarter saw revenue surge 25.6% and net profit rise 11.9% compared to the same quarter a year earlier. Margins have improved, with the net profit margin rising 0.4 percentage points to 9.1%, and returns remain stable at 11.8% return on equity and 11.1% return on capital employed.

Valuation multiples

The stock trades at 23.0 times earnings, a discount to the Healthcare median of 32.0, 2.83 times book value. It yields 1.5%.

Things to watch

The stock is 18.3% below its 52-week high, and domestic institutional holding fell 0.24 percentage points in the quarter. Foreign institutional holding also dropped 0.07 percentage points, and promoter holding increased only slightly, by 0.13 percentage points. The company's profit growth has slowed in the past five years, with a -10.2% CAGR, despite a strong 25.2% CAGR in the past three years.

Where it stands

Alembic Pharma's latest quarter showed strong revenue and net profit growth, with revenue up 25.6% and net profit rising 11.9%. The company's profit margin improved, and its return on equity remained stable. However, the stock is still 18.3% below its 52-week high, and institutional holdings have declined in the quarter. The company's five-year profit growth has been negative, despite strong recent performance.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.